Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Resolving pathogenicity classification for the CDH1 c.[715G>A] (p.Gly239Arg) Variant

Subjects

Abstract

Hereditary Diffuse Gastric Cancer (HDGC) syndrome is associated with CDH1 germline likely pathogenic/pathogenic variants. Carriers of CDH1 germline likely pathogenic/pathogenic variants are predisposed to diffuse gastric cancer and lobular breast cancer. This study aims to classify the CDH1 c.[715G>A] missense variant identified in a diffuse gastric cancer prone family by performing splicing studies. RT-PCR and subsequent cloning experiments were performed to investigate whether this variant completely disrupts normal splicing. This variant preferentially abolishes normal splicing through activation of a cryptic 3′ acceptor splice site within exon 6 of CDH1, presumably leading to a premature protein truncation within first extracellular domain repeat of E-cadherin protein. Our results contributed to evidence necessary to resolve pathogenicity classification of this variant, indicating that this variant is to be classified as pathogenic.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Fig. 1: Diffuse gastric cancer in a HDGC family with CDH1 c.[715G>A] variant.
Fig. 2: In silico tools predict CDH1 c.[715G>A] variant results in novel 3′ splice site.
Fig. 3: CDH1 c.[715G>A] mutant transcripts with novel acceptor splice site deletes 29 nucleotides from the 5′ end of exon 6.

References

  1. 1.

    Kaurah P, MacMillan A, Boyd N, Senz J, De Luca A, Chun N, et al. Founder and recurrent CDH1 mutations in families with hereditary diffuse gastric cancer. JAMA. 2007;297:2360–72.

    CAS  Article  Google Scholar 

  2. 2.

    Ansari S, Gantuya B, Tuan VP, Yamaoka Y. Diffuse gastric cancer: a summary of analogous contributing factors for its molecular pathogenicity. Int J Mol Sci. 2018;19:2424.

    Article  Google Scholar 

  3. 3.

    Hansford S, Kaurah P, Li-Chang H, Woo M, Senz J, Pinheiro H, et al. Hereditary diffuse gastric cancer syndrome: CDH1 mutations and beyond. JAMA. Oncol 2015;1:23–32.

    Article  Google Scholar 

  4. 4.

    Corso G, Marrelli D, Roviello F. E-cadherin germline missense mutations in diffuse gastric cancer. OA Cancer. 2013;1:4.

    Article  Google Scholar 

  5. 5.

    van Roy F, Berx G. The cell-cell adhesion molecule E-cadherin. Cell Mol Life Sci. 2008;65:3756–88.

    CAS  Article  Google Scholar 

  6. 6.

    Roberts ME, Ranola JMO, Marshall ML, Susswein LR, Graceffo S, Bohnert K, et al. Comparison of CDH1 penetrance estimates in clinically ascertained families vs families ascertained for multiple gastric cancers. JAMA Oncol. 2019;5:1325–31.

    Article  Google Scholar 

  7. 7.

    Figueiredo J, Melo S, Carneiro P, Moreira AM, Fernandes MS, Ribeiro AS, et al. Clinical spectrum and pleiotropic nature of CDH1 germline mutations. J Med Genet. 2019;56:199–208.

    CAS  Article  Google Scholar 

  8. 8.

    Lee K, Krempely K, Roberts ME, Anderson MJ, Carneiro F, Chao E, et al. Specifications of the ACMG/AMP variant curation guidelines for the analysis of germline CDH1 sequence variants. Hum Mutat. 2018;39:1553–68.

    Article  Google Scholar 

  9. 9.

    Oliveira C, Pinheiro H, Figueiredo J, Seruca R, Carneiro F. Familial gastric cancer: genetic susceptibility, pathology, and implications for management. Lancet Oncol. 2015;16:e60–70.

    Article  Google Scholar 

  10. 10.

    Kim S, Chung JW, Jeong TD, Park YS, Lee JH, Ahn JY, et al. Searching for E-cadherin gene mutations in early onset diffuse gastric cancer and hereditary diffuse gastric cancer in Korean patients. Fam Cancer. 2013;12:503–7.

    CAS  Article  Google Scholar 

  11. 11.

    Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17:405–24.

    Article  Google Scholar 

  12. 12.

    Petrova YI, Schecterson L, Gumbiner BM. Roles for E-cadherin cell surface regulation in cancer. Mol Biol Cell. 2016;27:3233–44.

    CAS  Article  Google Scholar 

  13. 13.

    Harrison SM, Rehm HL. Is ‘likely pathogenic’ really 90% likely? Reclassification data in ClinVar. Genome Med. 2019;11:72.

    Article  Google Scholar 

  14. 14.

    Shenoy S. CDH1 (E-Cadherin) mutation and gastric cancer: genetics, molecular mechanisms and guidelines for management. Cancer Manag Res. 2019;11:10477–86.

    CAS  Article  Google Scholar 

  15. 15.

    More H, Humar B, Weber W, Ward R, Christian A, Lintott C, et al. Identification of seven novel germline mutations in the human E-cadherin (CDH1) gene. Hum Mutat. 2007;28:203.

    CAS  Article  Google Scholar 

  16. 16.

    Susswein LR, Marshall ML, Nusbaum R, Vogel Postula KJ, Weissman SM, Yackowski L, et al. Pathogenic and likely pathogenic variant prevalence among the first 10,000 patients referred for next-generation cancer panel testing. Genet Med. 2016;18:823–32.

    CAS  Article  Google Scholar 

Download references

Funding

This study was funded by Department of Pathology, Memorial Sloan Kettering Cancer Center.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Liying Zhang.

Ethics declarations

Conflict of interest

LZ: Honoraria (Future Technology Research LLC, BGI, Illumina); Honoraria and Travel and accommodation expenses (Roche Diagnostics Asia Pacific). Family members hold leadership position and ownership interest of Decipher Medicine. ZKS: Immediate family member serves as a consultant for Allergan, Adverum Biotechnologies, Alimera Sciences, Fortress Biotech, Genentech/Roche, Novartis, Optos, Regeneron, Regenxbio, and Spark Therapeutics.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Yelskaya, Z., Arnold, A.G., Marcell, V.J. et al. Resolving pathogenicity classification for the CDH1 c.[715G>A] (p.Gly239Arg) Variant. Eur J Hum Genet (2021). https://doi.org/10.1038/s41431-021-00825-w

Download citation

Search

Quick links